论文部分内容阅读
匹莫苯(Pimobendan)是一个具有钙致敏作用和磷酸二酯酶抑制活性的正性肌力药,兼有血管扩张作用。 198例有症状的中、重度心力衰竭患者,维持洋地黄、利尿剂和血管扩张剂(主要是ACE抑制剂)治疗。随机口服安慰剂(49例)、匹莫苯每日2.5 mg(49例),5 mg(51例)、或10mg(49例,分2次),共治疗12周。治疗12周末,安慰剂组运动时间延长29.6±18.45秒,匹莫苯每日5 mg组则延长121.6±19.1秒(P<0.001);匹莫苯每日 10mg组运动时间延长81.8±19.5秒(与安慰剂组相比,P=0.05),每日2.5 mg组则与安
Pimobendan is a positive inotropic drug that has calcium-sensitizing and phosphodiesterase inhibitory activities and has vasodilator effects. 198 cases of symptomatic patients with moderate and severe heart failure, maintenance of digitalis, diuretics and vasodilators (mainly ACE inhibitors) treatment. Patients were randomly assigned to receive either placebo (49), pimobendan 2.5 mg (49), 5 mg (51), or 10 mg (49 in 2) for 12 weeks. After 12 weeks of treatment, the exercise time in the placebo group was prolonged by 29.6 ± 18.45 seconds and that in the pimobendin 5 mg group was prolonged by 121.6 ± 19.1 seconds (P <0.001), and that in the pimobendin 10 mg group was prolonged by 81.8 ± 19.5 seconds Compared with placebo, P = 0.05), daily 2.5 mg group was safe